Efficacy of rituximab in non-paraneoplastic autoimmune retinopathy

Efficacy of rituximab in non-paraneoplastic autoimmune retinopathy

Author Boudreault, Katherine Google Scholar
Justus, Sally Google Scholar
Sengillo, Jesse D. Google Scholar
Schuerch, Kaspar Google Scholar
Lee, Winston Google Scholar
Cabral, Thiago Autor UNIFESP Google Scholar
Tsang, Stephen H. Google Scholar
Abstract Background: Autoimmune retinopathy (AIR) is a rare but potentially blinding condition that is often underdiagnosed. Common features in AIR presentation include rapidly progressive vision loss with abnormal electrophysiological responses of the retina associated with positive anti-retinal antibodies. AIR is also challenging to treat, and thus, the introduction of new potential therapeutic agents is welcomed. The goal of this communication is to assess the effects of rituximab infusions on electroretinogram (ERG) responses and visual function outcomes in patients with non-paraneoplastic autoimmune retinopathy (npAIR). Results: Following infusion(s), three out of five patients showed no evidence of disease progression or improved, while two patients continued to progress on ERG. One patient demonstrated improvement in visual acuity (2 lines) in both eyes. ERG responses provided objective monitoring of patients' visual function and response to immunosuppression over time. Conclusions: These findings suggest that patients with npAIR unresponsive to other immunosuppression therapies may benefit from rituximab infusion, although stabilization rather than improvement was more frequently the outcome in our case series. Furthermore, regularly scheduled ERG follow-up examinations are recommended for monitoring patients' progression during treatment.
Keywords Autoimmune retinopathy
Rituximab
Treatment
Multi-modal imaging
Electroretinography
xmlui.dri2xhtml.METS-1.0.item-coverage London
Language English
Sponsor National Institutes of Health
National Cancer Institute Core
Research to Prevent Blindness (RPB)
RPB, New York, NY, USA
RPB
International Council of Ophthalmology - Retina Research Foundation
Tistou and Charlotte Kerstan Foundation
Schneeweiss Stem Cell Fund, New York State
Foundation Fighting Blindness New York Regional Research Center
Crowley Family Fund
Gebroe Family Foundation
Grant number National Institutes of Health: 5P30EY019007
National Institutes of Health: R01EY018213
National Institutes of Health: R01EY024698
National Institutes of Health: R01EY026682
National Institutes of Health: R21AG050437]
National Cancer Institute Core: 5P30CA013696
RPB
International Council of Ophthalmology - Retina Research Foundation
Tistou and Charlotte Kerstan Foundation
Schneeweiss Stem Cell Fund: C029572
Foundation Fighting Blindness New York Regional Research Center: C-NY05-0705-0312
Crowley Family Fund
Gebroe Family Foundation
Date 2017
Published in Orphanet Journal Of Rare Diseases. London, v. 12, p. -, 2017.
ISSN 1750-1172 (Sherpa/Romeo, impact factor)
Publisher Biomed Central Ltd
Extent -
Origin http://dx.doi.org/10.1186/s13023-017-0680-7
Access rights ACESSO ABERTO
Type Article
Web of Science ID WOS:000405839900001
URI https://repositorio.unifesp.br/handle/11600/53445

Show full item record




File

Name: WOS000405839900001.pdf
Size: 13.55Mb
Format: PDF
Description:
Open file

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account